PORTLAND, Oregon, January 19, 2021 — Health Technology Innovations, Inc. (HTI) today announced that Dr. Jeff King is joining HTI as a Senior Advisor. Dr. King is CEO and co-founder of Virogenomics BioDevelopment, Inc. (VBD), a biotechnology research and development company that collaborates extensively with scientists at Oregon Health and Science University (OHSU) who are developing technology with potential commercial applications. Prior to founding VBD Dr. King was Director of Bioinformatics and later COO and CEO of Virogenomics, Inc. At Virogenomics and VBD Dr. King held collaborator or PI roles on over $17M in non-dilutive SBIR and STTR awards for diagnostic and drug development projects. Dr. King was Senior Manager of Lead Validation at Rosetta Inpharmatics (acquired by Merck in 2001) and was Manager of Compound Profiling at Acacia Biosciences. Dr. King received a B.S. degree in Engineering Physics from the University of Arizona and a Ph.D. degree in Biophysics from the University of California, Berkeley. Prior to working in the biotechnology industry, he was an Assistant Research Molecular Biologist at the University of California, San Francisco and a Human Frontier Postdoctoral Fellow at the University of Bern in Switzerland.
